Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer (Q36028719)

11 August 2017

1 reference

title

Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer (English)

1 reference

11 August 2017

1 reference

Lorusso D

1

1 reference

11 August 2017

Ferrandina G

2

1 reference

11 August 2017

Lo Voi R

3

1 reference

11 August 2017

Fagotti A

4

1 reference

11 August 2017

Scambia G

5

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

published in

Journal of Chemotherapy

1 reference

11 August 2017

volume

16 Suppl 4

1 reference

11 August 2017

page(s)

98-103

1 reference

11 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

21 January 2018

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Second-line treatment of ovarian cancer with single-agent gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Phase II study of liposomal doxorubicin in advanced gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.98

10.1179/JOC.2004.16.SUPPLEMENT-1.98

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference